Drug Trial Radar · NCT05890352
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
227
Planned (sponsor's estimate)
Start
Sep 26, 2023
Primary completion
Dec 1, 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI); BeiGene; Ipsen; Incyte Corporation
- First posted
- Jun 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or did not respond to earlier treatment. Tazemetostat is in a class of medications called EZH2 inhibitors. It helps to stop the spread of cancer cells. Zanubrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells in the bone marrow. The addition of tazemetostat or zanubrutinib to tafasitamab and lenalidomide may be able to shrink the cancer or extend the time without cancer symptoms coming back.
Conditions
- Grade 3b Follicular Lymphoma
- High Grade B-Cell Lymphoma
- High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Transformed Non-Hodgkin Lymphoma
Interventions
Biospecimen CollectionProcedure
Undergo optional collection of blood
Computed TomographyProcedure
Undergo PET/CT and CT
LenalidomideDrug
Given PO
Magnetic Resonance ImagingProcedure
Undergo MRI
Positron Emission TomographyProcedure
Undergo PET/CT
Quality-of-Life AssessmentOther
Ancillary studies
Questionnaire AdministrationOther
Ancillary studies
TafasitamabBiological
Given IV
TazemetostatDrug
Given PO
ZanubrutinibDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: From date of randomization to date of first observation of progressive disease according to the 2014 Lugano classification, or death due to any cause, assessed up to 3 years
- Trial Outcome Index (TOI) score from the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) (Patient Reported Outcome [PRO] Study)Time frame: Baseline up to 3 months after randomization
Locations
104 sites in 1 country. Site status is shown where the registry gives one.
Banner University Medical Center - Tucson
Tucson, Arizona · Recruiting
University of Arizona Cancer Center-North Campus
Tucson, Arizona · Recruiting
Tower Cancer Research Foundation
Beverly Hills, California · Recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
City of Hope Seacliff
Huntington Beach, California · Recruiting
City of Hope Antelope Valley
Lancaster, California · Recruiting
City of Hope at Long Beach Elm
Long Beach, California · Recruiting
Cedars Sinai Medical Center
Los Angeles, California · Recruiting
City of Hope Newport Beach
Newport Beach, California · Recruiting
City of Hope South Pasadena
South Pasadena, California · Recruiting
City of Hope South Bay
Torrance, California · Recruiting
City of Hope Upland
Upland, California · Recruiting
Holy Cross Hospital
Fort Lauderdale, Florida · Recruiting
Mount Sinai Medical Center
Miami Beach, Florida · Suspended
University of Illinois
Chicago, Illinois · Recruiting
University of Chicago Comprehensive Cancer Center
Chicago, Illinois · Recruiting
Carle at The Riverfront
Danville, Illinois · Recruiting
Carle Physician Group-Effingham
Effingham, Illinois · Recruiting
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois · Recruiting
UC Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois · Recruiting
University of Chicago Medicine-Orland Park
Orland Park, Illinois · Recruiting
Memorial Hospital East
Shiloh, Illinois · Recruiting
Carle Cancer Center
Urbana, Illinois · Recruiting
Northwest Cancer Center - Main Campus
Crown Point, Indiana · Recruiting
Northwest Oncology LLC
Dyer, Indiana · Recruiting
Northwest Cancer Center - Hobart
Hobart, Indiana · Recruiting
Saint Mary Medical Center
Hobart, Indiana · Recruiting
Saint Catherine Hospital
Indianapolis, Indiana · Recruiting
The Community Hospital
Munster, Indiana · Recruiting
Women's Diagnostic Center - Munster
Munster, Indiana · Recruiting
Northwest Cancer Center - Valparaiso
Valparaiso, Indiana · Recruiting
UI Health Care Mission Cancer and Blood - Ankeny Clinic
Ankeny, Iowa · Suspended
Mercy Hospital
Cedar Rapids, Iowa · Recruiting
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa · Recruiting
UI Health Care Mission Cancer and Blood - West Des Moines Clinic
Clive, Iowa · Suspended
Mercy Medical Center - Des Moines
Des Moines, Iowa · Recruiting
UI Health Care Mission Cancer and Blood - Laurel Clinic
Des Moines, Iowa · Suspended
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Ann Arbor, Michigan · Recruiting
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton, Michigan · Recruiting
Trinity Health Medical Center - Brighton
Brighton, Michigan · Recruiting
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.